Catalyst Pharmaceuticals (CPRX) EBITDA (2010 - 2026)

Catalyst Pharmaceuticals has reported EBITDA for 17 years, with the latest figure at $63.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 12.51% year-over-year to $63.7 million; the trailing twelve-month figure through Mar 2026 stood at $221.3 million (up 12.17% YoY), and the FY2025 full-year result was $214.3 million, up 30.7% from the prior year.
• EBITDA for Q1 2026 stood at $63.7 million, up from $52.7 million in the prior quarter.
• The five-year high for EBITDA was $63.7 million in Q1 2026, with the low at -$30.8 million in Q3 2023.
• Historically, EBITDA has averaged $35.1 million across 5 years, with a median of $37.8 million in 2023.
• Annual changes were most pronounced in 2023 — EBITDA sank 234.3% — and 2024, when it surged 242.63%.
• Catalyst Pharmaceuticals' EBITDA stood at $25.5 million in 2022, then soared by 36.84% to $34.8 million in 2023, then soared by 60.72% to $56.0 million in 2024, then slipped by 5.9% to $52.7 million in 2025, then grew by 20.96% to $63.7 million in 2026.
• The last three EBITDA figures came in at $63.7 million (Q1 2026), $52.7 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.